Skip to main content
SpringerLink
Log in

Cetuximab

  • Chapter
  • First Online:
Adverse Events with Biomedicines

  • 1247 Accesses

Abstract

Cetuximab (Erbitux®, Eli Lilly) is a recombinant, human-murine chimeric monoclonal IgG1k antibody that specifically binds to the extracellular domain of the human epidermal growth factor receptor (EGFR). EGFR expression and upregulation occurs in 60–80 % of colorectal carcinoma (CRC).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Erbitux (Cetuximab) BLA 125084 Medical Review, FDA 2004

    Google Scholar 

  2. Erbitux (Cetuximab) Product Monograph ImClone LLC & BMS, Canada 2010

    Google Scholar 

  3. Erbitux (Cetuximab) EPAR WC500029119 Annex I, EMA 2012

    Google Scholar 

  4. Erbitux (Cetuximab) Prescribing Information BMS-Lilly 2012

    Google Scholar 

  5. Mehra R, Cohen RB, Burtness BA (2008) The role of cetuximab for the treatment of squamous carcinoma of head and neck. Clin Adv Hematol Oncol 6:742–750

    Google Scholar 

  6. Saltz LB, Lenz H-J, Kindler HL et al (2007) Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25: 4557–4561

    Google Scholar 

  7. Segal NH, Reidy-Lagunes D, Capanu M et al (2009) Phase II study of bevacizumab in combination with cetuximab plus irinotecan inn irinotecan refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (the BOND 2.5 study). J Clin Oncol (Meeting Abstracts) May 2009 vol 27 no 15S 4087

    Google Scholar 

  8. Stintzing S, Fischer von Weikersthal L, Decker T et al (2012) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumors in the randomized German AIO study KRK-0306. Ann Oncol 23:1693–1699

    Google Scholar 

  9. Golay J, Introna M (2012) Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys 526:146–153

    Google Scholar 

  10. Oliveras-Ferraros C, Cufi S, Queralt B et al (2012) Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signaling contribute to cetuximab resistance in wild-type KRAS tumor cells. BJC 106:1406–1414

    Google Scholar 

  11. Vincenzi B, Santini D, Tonini G et al (2006) New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor. J Clin Oncol 24:1957–1958

    Google Scholar 

  12. Chung CH, Mirakhur B, Chan E et al (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. NEJM 358:1109–1117

    Google Scholar 

  13. Ghaderi D, Taylor RE, Padler-Karavani V, et al (2010) Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nature Biotechnol 28:863–867

    Google Scholar 

  14. O’Neil BH, Allen R, Spigel DR et al (2007) High incidence of cetuximab related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 25: 3644–3648

    Google Scholar 

  15. Correale P, Botta C, Cusi MG et al (2012) Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T cell response in vitro. IJC 130:1577–1589

    Google Scholar 

  16. Chirmule N, Jawa V, Meibohm B (2012) Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. The AAPS J 14: 296–302

    Google Scholar 

  17. Tan AR, Moore DF, Hidalgo M (2006) Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 12:6517–6522

    Google Scholar 

  18. Agero ALC, Dusza SW, Benvenuto-Andrade C et al (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Amer Acad Dermatol 55:657–670

    Google Scholar 

  19. Ma BBY, Kam MKM, Leung SF et al (2012) A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol 23:1287–1292

    Google Scholar 

  20. Kang MJ, Hong YS, Kim K et al (2012) Biweekly cetuximab plus Irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Invest New Drugs 30:1607–1613

    Google Scholar 

  21. Argiris A, Feinstein TM, Wang L et al (2012) Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. Invest New Drugs 30:1575–1584

    Google Scholar 

  22. Schønnemann KR, Yilmaz M, Bjerregaard JK et al (2012) Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-esophageal cancer. Eur J Cancer 48:510–517

    Google Scholar 

  23. Nieder C, Pawinski A, Dalhaug A et al (2012) A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer. Radiation Oncol 7:3 (1–7)

    Google Scholar 

  24. Inoue K, Narukawa M, Takeuchi M (2012) Factors affecting efficacy and safety of add-on combination chemotherapy for non-small-cell lung carcinoma: a literature-based pooled analysis of randomized controlled trials. Lung 190:355–364

    Google Scholar 

  25. Ko AH, Youssoufian H, Gurtler J et al (2012) A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs 30:1597–1606

    Google Scholar 

  26. Hasselbalch B, Lassen U, Hansen S et al (2010) Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro-Oncology 12:508–516

    Google Scholar 

  27. Garden BC, Wu S, Lacouture ME (2012) The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Amer Acad Dermatol 67:400–408

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Verona, Verona, Italy

    Giuseppe Tridente

Authors
  1. Giuseppe Tridente
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Tridente .

1 Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLS 97.5 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this chapter

Cite this chapter

Tridente, G. (2014). Cetuximab. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_15

Download citation

Publish with us

Policies and ethics

Search

Navigation